Rituximab and Fludarabine Combination Produces Long-Term Remissions in CLL
Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate
XGEVA not Inferior to Zometa In 1,776-Patient Phase III Study
Study Suggests Biomarker For Resistance to Tamoxifen
Radiation, Tamoxifen After Surgery Reduce Breast Cancer Occurrence
Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint
Patients Who Smoke In Treatment Do Worse Than Those Who Quit
Dendritic Cell Vaccine May Boost Median Survival
Decline In Breast Cancer May Be Related to Drop In HT
Triple-Negative Breast Cancer Increases With Number of Births
PSA Velocity Poor Predictor Of Prostate Cancer Occurrence
Statins Associated With Lower Risk Of High-Grade Prostate Cancer
Mentholated Cigarettes Cause No More Lung Cancer, Deaths
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves BMS’s Yervoy For Metastatic Melanoma
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
